Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease
Brian G. Feagan(Western University), Chenglong Han(Janssen (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Susan D. Mathias(Health Outcomes Solutions (United States)), Kuan‐Hsiang Gary Huang(Janssen (United States)), Yan Liu(Ministry of Education of the People's Republic of China), Marion Vetter(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Matthew Germinaro(Johnson & Johnson (United States))
Cited by 16
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k